Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
S&P Biotech SPDR (NY: XBI)
77.87 USD  -2.21 (-2.76%)
Official Closing Price  /  Updated: 5:48 PM EST, Dec 13, 2018  /  Add to My Watchlist      
View: Quote News
Fund Overview
S&P Biotech SPDR
Sector
Exchange Traded NY
Net Assets 4.21B
Inception Date
Related Funds
Quote
Price 77.87
Volume 6,048,079
Last Trade Dec 13, 5:48pm
Change (%)
-2.21 (-2.76%)
Prev. Close 80.08
YTD %
-10.71%
Dividend Yield 0.29%
Performance
YTD
-9.34 (-10.71%)
1 Month
+0.21 (0.27%)
3 Month
-18.36 (-19.08%)
6 Month
-19.31 (-19.87%)
1 Year
-3.82 (-4.68%)
Chart
Charting
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in ... Read More
from Benzinga
Look to these stock market sectors in 2019 instead of FAANGs and tech
Put money into utilities, big pharma, consumers, gold, and cannabis, writes Jeff Reeves. Read More
from MarketWatch
Top News
More News
The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... Read More
from Benzinga
Sell on the Pop Prospects: December 12 Edition
Here is a look at ETFs that currently offer attractive short selling opportunities. The ETFs included in this list are rated as sell candidates for two reasons. First, each of these funds is deemed to... Read More
from ETFdb
The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... Read More
from Benzinga
3 Top Biotech Stocks to Buy in December
Find out why our team of healthcare experts believe that these biotechs are great buys right now. Read More
from Motley Fool
The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
Biotech stocks pulled back in last week. Incidentally, some large-cap biotech stocks were hitting new peaks even amid the sectoral ... Read More
from Benzinga
Noteworthy ETF Outflows: XBI, TSRO, ACAD, IONS
Symbols mentioned in this story: XBI, TSRO, ACAD, IONS Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... Read More
from ETF Channel
The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... Read More
from Benzinga
Analysts Expect 66% Upside For XBI
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... Read More
from ETF Channel
The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering
Here's a roundup of top developments in the biotech space over the past 48 hours. Scaling The Peak (Biotech stocks hitting ... Read More
from Benzinga
ETF Flows Report for 12/04/2018
. orttr { font-family: Arial; font-size: 12pt; font-weight: bold; height: 24px; } . Read More
from ETF Channel
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... Read More
from Benzinga
Monday's ETF Movers: XBI, XLV
In trading on Monday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 3.2% on the day. Components of that ETF showing particular strength include shares of Tesaro, up about 58.7% and... Read More
from ETF Channel
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a ... Read More
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X